Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.68 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9367631 | 0.95 | HCAR2 (0.68) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11365652 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11400467 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11241327 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11220652 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11409554 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL11231576 | 0.94 | HCAR2 (0.69) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL1259028 | 0.91 | HCAR2 (0.66) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL5724811 | 0.90 | HCAR2 (0.54) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 | |
| SCHEMBL25466120 | 0.86 | HCAR2 (0.50) | HCAR2HCAR3KMT2ANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638119-B | Pyrazole purine herbicide safener as well as preparation method and application thereof | 东北农业大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-118638119-A | Pyrazole purine herbicide safener as well as preparation method and application thereof | 东北农业大学 | 2024-09-13 | — | — | CN | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0411507-B1 | Pyrazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5183899-A | Cardiovascular disorders, hypotensive disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| EP-0411507-A1 | Pyrazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885KMT2A 2168/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885KMT2A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.